Preparation for treating and preventing metritis-mastitis-agalactia in sows and puerperal endometritis in cows

FIELD: veterinary science.

SUBSTANCE: the suggested preparation contains enrofloxacin, dimethyl sulfoxide, furacriline and distilled water at the following ratio of components, weight%: enrofloxacin 0.3-0.5, furacriline 0.021-0.027, dimethyl sulfoxide 38-50%, distilled water - the rest. The preparation should be introduced due to intrauterine injections, in sows - with the help of special equipment for artificial insemination. Against other analogs the preparation is of wider range of anti-microbial action and high anti-microbial activity.

EFFECT: higher efficiency of therapy and prophylaxis.

6 ex, 6 tbl

 

The invention relates to the field of veterinary medicine, in particular to medications for the treatment and prevention of metritis-mastitis-agalactia in sows and postpartum endometritis in cows.

Metritis-mastitis-agalactia - acute disease sows, emerging as a common syndrome in the first two days after farrowing and manifested by inflammation of the uterus, breast, and lower (hypogalactia) or termination (agalactia) secretion of milk. The disease manifests with fever to 39.8-40,8°C, increased heart rate and respiration, suppression of the General condition, decrease or stop taking food and water. Sows are not allowing piglets to the nipple. From the genital tract is allocated mucopurulent exudate liquid or semi-liquid consistency in the amount of from 10-20 up to 200-300 ml vulva, the vaginal mucosa hypermonogenic. The main form of inflammation of the mammary gland is subclinical mastitis, which affected up to 40-60% operating share of mammary glands of sows. Clinically expressed mastitis is logged in 12-20% of patients sows.

Acute postpartum endometritis - inflammation predominantly mucous membrane of the uterus. Depending on the nature of inflammation postpartum endometritis is divided into catarrhal, purulent-catarrhal and fibrinous. It is considered that the main form of manifestation of postpartum endometritis in cows is purulent-catarrhal endometritis. Acute postpartum endometritis clinically manifests itself in 8-10 days after birth, at least on 6-7 day and is characterized by excessive discharge of exudate (mucous, purulent mucous, fibrinous) liquid consistency gray-brown or yellow-brown color. Postpartum endometritis is logged in 20-57% calving cows.

For the treatment and prevention of postpartum diseases in sows using drugs antimicrobial action, including antibiotics, sulfa, nitrofuranovye funds. But not all of them are have the desired effect. This is primarily attributable to a decrease in the sensitivity of microflora of the uterus to the drugs. Therefore, the required periodic replacement drugs by decreasing their therapeutic efficacy and sufficient range of used rotary tools. In this connection there is a need to develop new effective drugs. As peers, we have taken two drugs used to treat sows patients metritis-mastitis-agalactia and treatment of cows patients with postpartum endometritis.

Neopor is a complex product containing neomycin, furazolidone and gelatin-glycerin base. Used for the treatment and prevention of inflammation in the uterus of animals. The main disadvantage of Neopor is a rapid decline in its therapeutic and prophylactic the efficiency due to the lower sensitivity of microflora and necessity of repeated administration in the absence of the basis of drug penetrating substances /1/.

Laporan - complex preparation containing chloramphenicol and furagin, dissolved in dimethyl sulfoxide /2/.

The main disadvantages of leporano are:

a) reducing its therapeutic efficacy due to rapid decrease in the sensitivity of microflora to chloramphenicol in connection with long-term (over 20 years) use of this antibiotic in pig production;

b) the high cost of the drug due to the large concentration (65%) of dimethyl sulfoxide (DMSO).

The closest analogue of the developed drug is a drug enrold /3/. Enrold represents 0.4% of enrofloxacin in solution of DMSO and distilled water.

The disadvantages of anroid are reducing its therapeutic efficacy associated with the development of microbial resistance to enrofloxacin. Found that this is due to disruption of the structure of DNA-gyrase, the enzyme that causes the replication of bacterial DNA, as well as reduced penetration of quinolones through the cell wall of bacteria /4/.

In addition, it is known that in one-component preparations containing one drug resistant bacteria are developing faster.

One of the measures preventing the development of resistance of microorganisms is the development of dosage forms, including several components with different mechanism an microblog actions. In the case where a combination of antibiotics does not cinergena effect, and limited adaptive action extends the action spectrum of the complex products, which is important in mixed infections. Integrated use of antibiotics is also effective when exposed to drug-resistant forms of microorganisms. They may use different mechanisms of influence on the microbial cell. Combined antibiotic therapy reduces the risk of drug resistance of microorganisms /5/.

Thanks to the synergistic action of the components of a comprehensive drug and therapeutic effect at lower doses will be able to reduce the toxicity of the individual components of /6/.

In connection with this part of the proposed drug, in addition to enrofloxacin, entered the drug nitrofuranovye series - furacilin, also with a wide spectrum of antimicrobial action.

The technical result of the invention is to increase efficiency, enhance spectrum and the enhancement of antimicrobial activity.

This goal is achieved by the use of integrated product consisting of enrofloxacin, furacilin, DMSO and distilled water. The preparation is applied by injecting it into the uterine cavity in patients metritis-wt is it agalactia sows and sick postpartum endometritis cows with curative intent and animals after farrowing and calving with the preventive purpose.

The claimed preparation consists of the following components, wt%:

Enrofloxacin 0,3-0,5

Furacilin 0,021-0,027

Dimethyl sulfoxide 38-50

Distilled water the Rest

The optimal ratio included in the composition of the product components is the following, wt%:

Enrofloxacin 0,4

Furacilin 0,025

Dimethyl sulfoxide 40

Distilled water the Rest

Enrofloxacin - derived finalchronicle acid belongs to the group of fluoroquinolones and third-generation consists of one radical of fluorine at position 6, one radical piperazinil in position 7 and radical of cyclopropyl at position 1 /7/.

Enrofloxacin trudnorastvorim in water, poorly soluble in ethanol; soluble in chloroform, in acidic and alkaline solutions.

Due to its structure enrofloxacin has the following advantages over many antibacterial drugs:

- active against gram-positive and gram-negative microorganisms, as well as mycoplasmas;

active when administered orally, as is well absorbed from the gastrointestinal tract and penetrates into all the organs and tissues of the body;

- low toxicity to animals and birds.

Enrofloxacin has a broad spectrum of antibacterial action, inhibiting the growth and development of gram-positive and gram-negative micro is organizmov, including E. coli, Haemophilus, Klebsiella, Pasteurella, Pseudomonas, Bordetella, Campylobacter, Erysipelothrix, Corynebacterium, Staphylococcus, Streptococcus, Actinobacillus, Clostridium, Bacteroides, Fusobacterium, and Mycoplasma gallisepticum, Mycoplasma synoviae, Mycoplasma meleagridis, Mycoplasma iowae.

Enrofloxacin blocks the effect of specific bacterial enzyme DNA gyrase. This enzyme is necessary for the promotion of coiled double helix DNA before replication. Enrofloxacin directly affects the subunit And that leads to stop of replication of DNA and the emergence of new bacteria.

Enrofloxacin directly associated with specific regions of DNA, which is usually associated DNA-gyrase. Thus fluoroquinolone prevents the beginning of replication.

The specific mechanism of action of fluoroquinolones, distinct from that of other antibacterial drugs, provided for enrofloxacin no cross-resistance to all antibiotics, sulfonamides and nitrofurans.

The absence of DNA-gyrase, the target for enrofloxacin, in mammals and birds does the drug is practically non-toxic to the microorganism.

So LD50after a single oral administration to chickens ranges from 2,000 to 2,500 mg/kg body weight, which is hundreds of times higher than therapeutic dose.

Furacilin - antimicrobial agent, broad-spectrum, has an antimicrobial on the op perate on gram-positive and gram-negative bacteria, especially pyogenic organisms. Highly active against the causative agents of dysentery, kalantaridou, listeriosis and antibiotic-resistant microbes. Furacilin low toxicity. The cumulative effect is not. When you assign inwards in therapeutic doses is well absorbed and within 6 hours remains in the blood in effective concentrations. Increases the phagocytic activity of leukocytes, does not affect the composition of the blood.

The mechanism of antimicrobial action furacilin based on the blocking of cellular respiration. As acceptors of hydrogen, they compete with flavins enzymes that disrupt the synthesis of nucleic acids by blocking structural gene DNA, inhibit the metabolism of pyruvate, the activity of dehydrogenases, aldolase and transketolase, which affects the energy metabolism of microbial cells, its growth and multiplication) /8/.

Dimethyl sulfoxide (DMSO) is used as the solvent. He is the only low-toxic substance which is able to penetrate intact tissue and carry the dissolved drug substance (penetrating and transport properties) /9/.

The inventive product is administered to sows intrauterine device artificial insemination of pigs - POS-5. In the treatment of a single dose of 0.7 ml/kg of body weight, if necessary, in titsa again after 24 hours. For prophylaxis, the dose is 0.5 ml/kg of body weight over 6-12 hours after farrowing, once.

The drug for treatment of cows with acute postpartum endometritis, introduced intrauterine using Janet's syringe 3-4 times (the first two times at a dose of 200 ml, and then 150 ml) at 48-hour intervals until recovery.

For the prevention of postpartum endometritis cows intrauterine once to enter the drug at a dose of 200 ml immediately after surgical separation of placenta or through 6-12 hours after normal childbirth in cases of wide prevalence of this pathology in the economy.

The drug is manufactured in the following way (components in wt.%). In DMSO (40%) entered furacilin 0.025% and mixed until dissolved, and thereto is gradually added 0.4% of enrofloxacin in aqueous solution and is added to distilled water to 100%.

Checking the efficiency of the drug was carried out on the sows nursery-agro JSC "Krasnodon" professionals from the district of the Volgograd region and the cows LLC Warniproduct" novousmansky district of Voronezh region.

The essence of the proposed technical solution is illustrated by examples.

Example 1.

The experiment was carried out on pigs of large white breed for the second-fourth farrowing. Diagnosis is made on the basis of clinical, obstetric-gynecologic about the surveys.

The drug was injected into the uterine cavity using a POS-5 in a dose of 0.7 ml/kg body weight in pre-heated to 40%. If effect after the introduction of the proposed drug is not obtained, then the drug was administered again. The experiment was carried out using three songs existing components of the claimed preparation:

No. 1 contains (wt.%): enrofloxacin 0,3, furacilin 0,021, dimethylsulfoxide 38 and distilled water to 100;

No. 2 contains (wt.%): enrofloxacin 0,4, furacilin 0,025, dimethylsulfoxide 40 and distilled water to 100;

No. 3: contains (wt.%) enrofloxacin 0,5, furacilin 0,027, dimethylsulfoxide 50 and distilled water to 100.

Animals of the control group was treated with basic drug Neopor. The suspension Neopor cooked estimated 3-4 candles in 150 ml of distilled water, was administered at 24-hour intervals until recovery in accordance with the instruction to the drug /1/.

For animals was performed daily clinical examination, taking into account the time of the disappearance of clinical signs of disease (t, pulse, respiration, allocation of the external genital organs, General condition, intake of food and water, state of piglets).

The results of the experiment are presented in table 1.

Table 1
Therapeutic effective is here stated and known drugs in the treatment of metritis-mastitis-agalactia in sows
IndicatorsUsing the base caseUsing different ratios of the components of the claimed drug
No. 1No. 2No. 3
The number of sick animals17201920
Therapeutic effect after a single intrauterine injection11 (64,7%)13 (65,0%)16 (84,2%)16 (80,0%)
Therapeutic effect after repeated administration newsgroups animals13 (76,5%)16 (80,0%)19 (100%)19 (95,0%)
Not recovered after double injection14 (23,5%)4 (20,0%)-1 (5,0%)
The incidence of mol shares. glands of sows after 5 days from the start of treatment (%)70,323,40,713,2

From table 1 it follows that the best therapeutic effect achieved with the use of a composition No. 2, containing (wt.%): enrofloxacin 0,4, furacilin 0,025, dimethylsulfoxide 40 and distilled water to 100.

Example 2.

The experiment was carried out on the sows of large white breed 2-5 the farrowing weighing 180-kg. Prevention metritis-mastitis-agalactia conducted by single intrauterine administration of the drug using POS-5 4-6 hours after farrowing at a dose of 50 ml per 100 kg body weight. The experiment was carried out using three songs existing components of the claimed preparation:

No. 1 contains (wt.%): enrofloxacin 0,3, furacilin 0,021, dimethylsulfoxide 38 and distilled water to 100;

No. 2 contains (wt.%): enrofloxacin 0,4, furacilin 0,025, dimethylsulfoxide 40 and distilled water to 100;

No. 3: contains (wt.%) enrofloxacin 0,5, furacilin 0,027, dimethylsulfoxide 50 and distilled water to 100.

Animals of the control group using the base case once intrauterine has introduced a suspension Neopor prepared based on 1 suppository in 50 ml of distilled water in 4 to 6 hours after farrowing.

Animals of the control group without the use of prototype no drugs after farrowing was not implemented.

For animals was performed daily clinical examination, taking into account the incidence of sows metritis-mastitis-agalactia and endometritis.

The results of the experiment are shown in table 2.

Table 2
The effectiveness declared and known drugs for the prevention metre the-mastitis-agalactia in sows
IndicatorsThe claimed preparation, compositionsUsing the base caseWithout the use of medication
No. 1No. 2No. 3
The number of animals in the experience2527272928
Endometritis1010111116
MMA42329
Healthy111513163

From table 2 it follows that the best preventive effect achieved with the use of a composition of existing components No. 2: enrofloxacin, furacilin and dimethyl sulfoxide in the ratio of 0.4:0,025:40,0.

Example 3.

The experiment was carried out on cows red-and-white breed 4-6 years of age. Diagnosis is based on clinical, obstetric and gynaecological examinations, anamnesis.

The drug was injected into the uterine cavity using a syringe Jean first two times at a dose of 200 ml, and then 150 ml of 48-hour intervals until clinical recovery. The experiment was carried out using three compositions applicable to the components of the claimed preparation:

No. 1 contains (wt.%): enrofloxacin 0,3, furacilin 0,021, dimethylsulfoxide 38 and distilled water to 100;

No. 2 contains (wt.%): enrofloxacin 0,4, furacilin 0,025, dimethylsulfoxide 40 and distilled water to 100;

No. 3: contains (wt.%) enrofloxacin 0,5, furacilin 0,027, dimethylsulfoxide 50 and distilled water to 100.

Animals of the control group was treated with basic drug - Neopor. The suspension Neopor cooked estimated 3-4 candles in 150-200 ml of distilled water, was administered to 48-hour intervals until recovery in accordance with the instruction to the drug /1/.

For animals was performed daily clinical examination, taking into account the time of the disappearance of clinical signs of disease, the number of recovered and fertilized animals, the rate of fertilization, the duration of the period from calving to insemination.

The results of the experiment are shown in table 3.

From table 3 it follows that the best therapeutic effect achieved with the use of a composition of existing components No. 2: enrofloxacin, furacilin and dimethyl sulfoxide in the ratio of 0.4:0,025:40,0.

Example 4.

The experiment was carried out on cows red-and-white breed 4-6 years of age. Prevention of postpartum endometritis were carried out by single intrauterine administration of the drug with the help of Janet's syringe immediately after surgical separation of placenta or 6-8 hours after a normal delivery at a dose of 200 ml. of the experiment was carried out using three songs existing components of the claimed preparation:

No. 1 contains (wt.%): enrofloxacin 0,3, furacilin 0,021, dimethylsulfoxide 38 and distilled water to 100;

No. 2 contains (wt.%): enrofloxacin 0,4, furacilin 0,025, dimethylsulfoxide 40 and distilled water to 100;

No. 3: contains (wt.%) enrofloxacin 0,5, furacilin 0,027, dimethylsulfoxide 50 and distilled water to 100.

Animals of the control group using the base case once intrauterine has introduced a suspension Neopor dose of 200 ml immediately after surgical separation of placenta or 6-8 hours after normal delivery /1/.

Animals of the control group without the use of prototype no drugs after farrowing was not implemented.

For animals was performed daily clinical nab Eugenie, given the incidence of cows postpartum endometritis, percentage of fertilized animals, the period from calving to insemination, the rate of fertilization.

The results are presented in table 4.

Table 3
Therapeutic efficacy declared and known drugs for the treatment of endometritis in cows
IndicatorsThe claimed preparation, compositionsThe basic version
No. 1No. 2the 3
The number of animals, goal12131312
Recovery time, days14,8±0,7813,3±0,4613,9±0,5115,4±0,67
The number of injections of drugs5,24±0,393,91±0,31as 4.02±0,285,69±0,24
Recovered, goal911109
Therapeutic effectiveness, %75,084,676,975,0
The period from calving to insemination, days79,1±3,0965,2±2,0768,4±2,4778,9±3,41
Were fertilized at the first insemination:
goal61097
%50,076,969,258,3
The rate of fertilization1,91±0,191,48±0,081,56±0,091,89±0,17
Toxic effects on goal0000
Table 4
The effectiveness declared and known drugs for the prevention of postpartum endometritis in cows
IndicatorsThe claimed preparation, compositionsUsing the base caseWithout the use of medication
No. 1No. 2No. 3
The number of animals, goal1112121212
Ill postpartum endometritis:
goal31235
%27,38,316,725,041,7
Prophylactic efficacy, %72,791,783,375,058,3
Perry is d from calving to insemination, days59,8±3,1446,7±2,1749,8±2,0758,1±3.04 from75,6±4,21
Were fertilized at the first insemination:
goal69875
%50,075,066,758,341,7
The rate of fertilization1,51±0,091,33±0,081,38±0,081,47±0,082,14±0,17
Toxic effects on goal00000

From table 4 it follows that the best preventive effect achieved with the use of a composition of existing components No. 2: enrofloxacin, furacilin and dimethyl sulfoxide in the ratio of 0.4:0,025:40,0.

Example 5.

To test the antimicrobial activity of the proposed drug in comparison with the prototype conducted an experiment. Claimed the drug was taken in the optimal current ratio, wt.%:

Enrofloxacin 0,4

Furacilin 0,025

Dimethyl sulfoxide 40

Distilled water the Rest

Defined antimicrobial act shall want to make (BS - the bacteriostatic activity, BC - bactericidal activity) of the proposed drug by the serial dilution method.

Table 5
Antimicrobial activity of the proposed drug and enrold
CultureThe drug concentration, g/ml
enroldthe claimed preparation
BSBCBSBC
Staph. aureus1,95a 3.91,01,0
E. coli On 8660,490,490,0150,03
E.coli 141a 3.97,81,95a 3.9
Str. agalactiae0,490,490,080,32

From table 5 it follows that the claimed product has higher antimicrobial activity compared to enrollm.

Example 6.

To determine the sensitivity of microflora isolated from the uterus of patients with endometritis cows and sows to the claimed drug and aquazide conducted an experiment. Claimed the drug was taken in the optimal ratio applicable to the of mponents, wt.%:

Enrofloxacin 0,4

Furacilin 0,025

Dimethyl sulfoxide 40

Distilled water the Rest

Sensitivity of the isolated microflora determined using the indicator disk.

Table 6
The sensitivity of microflora to the claimed drug and aquazide
CultureThe zone of growth inhibition (mm
enroldThe claimed preparation
E. coli 86*24
E. coli Of 1261327
Staph. aureus1528
Staph. epidermidis1324
Str. β-haemolytic718
Str. agalactiae1824
Str. disagalactiae1227
*Note: when the zone of growth inhibition of less than 10 mm, the microorganisms are considered to be insensitive, when the zone of growth inhibition of 10 to 15 mm - insensitive, from 15 to 20 mm - sensitive and more than 20 mm - sensitive.

From table 6 it follows that the claimed product has a broader spectrum of anti-Christ. mikrobnogo actions as almost all of the selected microorganisms exhibit high sensitivity.

Thus, studies have shown the effectiveness of the proposed drug and its wide range of actions for the treatment and prevention of metritis-mastitis-agalactia in sows and postpartum endometritis in cows.

Sources of information

1. Worms D.K. and other Drugs in veterinary medicine. - M.: Kolos, 1977. - S.

2. Sotnikov AV Diagnosis and treatment of subclinical mastitis in MMA (metritis-mastitis-agalactia) in sows. / The dissertation on competition of a scientific degree of the candidate of veterinary Sciences. - Voronezh, 1985.

3. Interim guidance on the use of the drug enrold for the prevention and treatment of obstetric gynecological diseases in cows and sows (in the order of the extensive production tests in 2000-2002) No. 13-5-2/2007. Approved by the veterinary Department of the Ministry of agriculture of Russia 15.05.2000,

4. .Gellert. DNA topoisomerases / Ann. Rev. Biocem. - 1981. - V.50. - P.879-910.

5. Kovalev V.F. and other Antibiotics in animal products. - M., 1977.

6. Rabinovich M.I. Workshop on veterinary pharmacology and formulation. / 3rd ed., Corr. and extra - Agropromizdat, 1988. - 239 S.

7. Sazonova EM. Development of antibiotic on the basis of enrofloxacin, a study of its toxicity, pharmacokinet the IKI and therapeutic efficacy. / The dissertation on competition of a scientific degree of candidate of biological Sciences. - Voronezh, 2000.

8. Kovalev V.F., wolves IB, Violin BV Antibiotics, sulfonamides and nitrofurans in veterinary medicine: a Handbook // Agropromizdat, 1988.

9. Dimethyl sulfoxide: pharmacology, application in dermatology and related specialties. - Perm, 1975.

Drug for the treatment and prevention of metritis-mastitis-agalactia in sows and postpartum endometritis in cows containing enrofloxacin, dimethylsulfoxide and distilled water, characterized in that it further comprises furacilin in the following ratio, wt.%:

Enrofloxacin0,3-0,5
Furacilin0,021-0,027
The sulfoxide38-50
Distilled waterRest



 

Same patents:

FIELD: medicine, gynecology.

SUBSTANCE: invention relates to an agent used in treatment of vasomotor and emotional-vegetative symptoms of climacteric syndrome and the corresponding method for treatment. Method involves using dried defibrinated or non-defibrinated blood of Siberian stag, Manchurian wapity or sika deer (females or males). Agent is prescribed by oral route administration in the dose 25 mg (1 capsule), 2 times per a day for 25-35 days. Dried defibrinated or non-defibrinated blood of Siberian stag, Manchurian wapiti or sika deer enhances the level of estradiol and declines the level of follicle-stimulating hypophysis hormone in serum blood that provides the clinical effectiveness of treatment.

EFFECT: valuable medicinal properties of agent.

3 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves administering hormone composition comprising 0.5-3.0 mg of estrogen (estradiol, free or etherified conjugated horse estrogen) and 1.5-3.75 mg of nomegestrol acetate for treating estrogen insufficiency cases and stopping ovulation.

EFFECT: enhanced effectiveness of treatment in menopause period without bleeding.

8 cl, 6 tbl

FIELD: medicine.

SUBSTANCE: method involves administering hormone composition comprising 0.5-3.0 mg of estrogen (estradiol, free or etherified conjugated horse estrogen) and 1.5-3.75 mg of nomegestrol acetate for treating estrogen insufficiency cases and stopping ovulation.

EFFECT: enhanced effectiveness of treatment in menopause period without bleeding.

8 cl, 6 tbl

FIELD: medicine, contraception.

SUBSTANCE: invention proposes antibacterial and contraceptive compositions that comprise the following components: (1) matrix-forming substance; (2) bioadhesive substance; (3) buffer substance; (4) moistening substance, optionally; (5) preserving agent, optionally, and (6) water. Proposed compositions are suitable for their placement into vagina wherein compositions form semisolid matrix in contact with testicular fluid, cause thickening cervical mucus, form a bioadhesive layer on vagina surfaces, maintain the natural acid pH value in vagina about less 5 in the presence of testicular fluid ejected by a male and don't disturb essentially the natural microbiological balance in vagina. Compositions and methods decrease and/or prevent transfer of diseases transferring by sexual way and act as vaginal contraceptives with less adverse effect as compared with conventional vaginal contraceptives and can be used therefore for a long time. Compositions and methods are simple for using and don't require a physical device for their retention into vagina during using.

EFFECT: improved and valuable properties of compositions and methods.

36 cl, 17 tbl, 11 ex

FIELD: medicine, biotechnology.

SUBSTANCE: invention relates to a method for preparing biopreparation. Invention relates to the development of preparation possessing an antibacterial spectrum effect from products obtained in process of purification of interferon. The preparation comprises low-molecular peptides with molecular mass less 3 kDa. Invention provides the more complete using products in process of interferon preparing, decrease of waste formed in process and increase yield of useful product.

EFFECT: improved preparing method.

5 tbl

FIELD: veterinary science.

SUBSTANCE: method involves using cow placenta extract with hazel nut that is injected in cow in region of ischio-rectal fossula from both sides in deep 5-8 cm in the dose 0.09-0.11 ml per kg of animal mass. Dose is separated for two parts: the first injection - after delivery immediately and the second injection - 22-26 h later after the first injection. Method enhanced quality of prophylaxis of delivery and postdelivery pathology.

EFFECT: improved prophylaxis method.

FIELD: veterinary science.

SUBSTANCE: method for increasing cow embryos survival involves a single intramuscular administration gonadoliberin surfagon in the dose 10 mcg to cows on 8-10 days after insemination followed by additional injection of thymogen in the dose 5 mcg/kg of body mass on 8, 9 and 10 days. Method provides maintenance of hormonal activity of yellow body in cows.

EFFECT: improved increasing method.

1 tbl, 1 ex

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

FIELD: veterinary science.

SUBSTANCE: preparation for treatment and prophylaxis of endometritis in cows comprises antibacterial substance dioxydin, gelatin, glycerol and distilled water wherein food or medicinal gelatin is used as gelatin source, distilled glycerol if the 1-st grade is used glycerol source and comprises additionally resorcinol and veterinary algalipin in the following ratio of components, g: dioxydin, 0.1-0.3; resorcinol, 0.01-0.02; veterinary algalipin, 0.9-1.1; food or medicinal gelatin, 1.5-2.0; distilled glycerol of the 1-st grade, 5.0-5.4, and distilled water, 2.1-2.6. Invention provides enhancing effectiveness of the preparation and fertilization in cows.

EFFECT: improved and valuable veterinary properties of preparation.

3 tbl

FIELD: medicine.

SUBSTANCE: method involves additionally administering vitamins B6, B12 and folic acid to patients receiving anticoagulation therapy. Protein content is limited in daily food allowance to 0.8-1.1 g/kg of body weight and cysteine content is increased to 400-500 mg/day.

EFFECT: enhanced effectiveness of treatment; eliminated homocysteine link in pathogenesis.

FIELD: medicine.

SUBSTANCE: method involves administering drugs usable for hindering keratoleukoma occurring after carrying out excimer laser keratectomy with an antioxidant agent being added. The agent is used for jet irrigating cornea before setting lens.

EFFECT: enhanced effectiveness in reducing lipid peroxidation products quantity; accelerated cornea epithelialization.

2 cl, 2 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: as the main preparation it is necessary to apply "Prospidin" to keep and improve visual functions. The innovation suggested is considered to be more available and cheaper for patients against other well-known methods.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: organic chemistry of heterocyclic compounds, biochemistry.

SUBSTANCE: invention relates to new ortho-substituted and N-substituted indoles of the formula (α): or (β): or their pharmaceutically acceptable salts wherein Z1 represents -CR4 or nitrogen atom (N); R4 means hydrogen atom (H), (C1-C6)-alkyl comprising optionally oxygen atom (O) or nitrogen atom (N) possibly substituted with halogen atom, keto-group, 5-6-membered cycloaliphatic radical possibly comprising 1-2 oxygen atoms (O) or nitrogen atom (N); Z2 represents -CH or -CR wherein R means (C1-C6)-alkyl; R1 means compound of the formula: wherein X1 means -CO or its isostere; m = 0, 1; Y represents alkyl that can be substituted; or two Y form in common (C2-C3)-alkylene; n = 0, 1 or 2; Z3 represents -CH; X2 represents -CH, -CH2 or their isostere; Ar represents one or two phenyl groups bound with X2 wherein phenyl can be substituted; R2 represents hydrogen atom (H), (C1-C6)-alkyl or aryl wherein each aryl comprises, possibly, oxygen atom (O) or nitrogen atom (N) and can be substituted. Proposed compounds are selective inhibitors of p38α kinase.

EFFECT: valuable biochemical properties of compounds.

34 cl, 5 tbl, 23 ex

FIELD: medicine.

SUBSTANCE: method involves instilling 0.5% Dioxidine solution concurrently with Enterosgel into urinary bladder in volume proportion of 1:1.

EFFECT: enhanced effectiveness of treatment; reduced toxic side action.

1 tbl

FIELD: organic chemistry, pharmaceuticals.

SUBSTANCE: invention relates to new 1,3-dioxolane derivatives of formula 1 wherein Ra and Rb are independently hydrogen or C1-C6-alkyl; or Ra and Rb together with the carbon atom to which they are attached form optionally substituted 4-7-membered ring. Methods for production of said compounds and optical resolution thereof also are disclosed. Compounds of present invention are useful as synthetic intermediates for (-)-3-(4-phenyl-1-piperasinyl)-1,2-propanediol and salts thereof having antitussive activity.

EFFECT: new 1,3-dioxolane derivatives useful in pharmaceutical production.

8 cl, 8 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention describes bicyclic N-acylated imidazo-3-amines or imidazo-5-amines salts of the general formula (I): wherein R1 means tert.-butyl, 1,1,3,3-tetramethylbutyl, (C4-C8)-cycloalkyl, phenyl disubstituted with (C1-C4)-alkyl, -CH2Ra wherein Ra means the group -CO(OR') wherein R' means (C1-C8)-alkyl; R2 means hydrogen atom, the group -CORb wherein Rb means (C1-C8)-alkyl or (C3-C8)-cycloalkyl; R3 means (C1-C8)-alkyl, (C3-C8)-cycloalkyl, phenyl, pyridyl, furfuryl or thiophenyl; A means tri-linked fragment of ring of the formula: wherein R6 and R7 mean hydrogen atom or tetra-linked fragment of ring of the following formulae: wherein R4' means hydrogen atom or benzyloxy-group; R5' means hydrogen atom; R6' means hydrogen atom, (C1-C8)-alkyl or nitro- (NO2)-group; R7' means hydrogen atom, (C1-C8)-alkyl, or R6' and R7' mean in common the following fragment of ring: -CRi=CRj-CH=CH- wherein Ri and Rj mean hydrogen atom; R5'' means hydrogen, chlorine atom or (C1-C8)-alkyl; R6'' means hydrogen atom; R7''n means hydrogen atom, amino- (NH2)-group or (C1-C8)-alkyl; R4''', R6''' and R7''' mean hydrogen atom; R8 means (C1-C8)-alkyl or (C3-C8)-cycloalkyl; X means anion of inorganic or organic acid, or their acid-additive compounds. Also, invention relates to a method for their preparing and a pharmaceutical composition based on thereof. These new compounds show affinity to opiate μ-receptor and can be used, in particular, as analgesic agents.

EFFECT: improved preparing method, valuable medicinal properties of compounds and pharmaceutical compositions.

12 cl, 2 dwg, 32 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to arylsulfonyl derivatives of the formula (I): , wherein Ar means naphthyl or phenyl substituted optionally with halogen atom or (C1-C6)-alkoxy-group; R1 means (C1-C6)-alkyl; R2 means hydrogen atom or (C1-C6)-alkyl, or their pharmaceutically acceptable salts or solvates. Proposed compounds show affinity to HT6 receptors. Also, the claim describes pharmaceutical compositions comprising indicated compounds, their using as therapeutic agents and a method for their preparing. Compounds can be useful in treatment of some disturbances in the central nervous system (CNS).

EFFECT: improved preparing method, valuable medicinal properties of compounds and composition.

12 cl, 1 tbl, 12 ex

FIELD: medicine, oncology.

SUBSTANCE: invention relates to method for malignant tumor treatment (including cancer, sarcoma, melanocytoma) in human by ectasceine ET743 intravenous infusion in dose of 500-1650 mug/m2 of surface are; to similar treatment by combination of ET743 with antiemetic agent; as well as to relative composite preparation. Method of present invention provides clinical amelioration in subject suffering from progressive or metastasing cancer and improves treatment effectiveness of diseases being progressed after known chemotherapy.

EFFECT: new effective method for cancer treatment; drug with good acceptability.

31 cl, 3 ex, 1 tbl

FIELD: organic chemistry, biochemistry, enzymes.

SUBSTANCE: invention relates to biologically active compounds. Invention represents dipeptide nitrile inhibitors of cathepsin K, their pharmaceutically acceptable salts or their esters of the general formula:

wherein X means -CH or nitrogen atom (N); R means (C1-C7)-(lower)-alkyl, (C1-C7)-(lower)-alkoxy-(C1-C7)-(lower)-alkyl, (C5-C10)-aryl-(C1-C7)-(lower)-alkyl or (C3-C8)-cycloalkyl.

EFFECT: valuable biochemical properties of compounds.

6 cl, 12 ex

FIELD: veterinary science.

SUBSTANCE: invention involves the combined use of antibacterial preparations and immunomodulator. Method involves complex of single and double RNA sodium salts from killer yeast Saccharomyces cerevisiae as an immunomodulator and synthetic polymer-carrier taken in the dose 0.3-0.4 mg/kg. Immunomodulator is administrated in animals in a single dose before onset of critical period, i. e. in 15-20 days of piglets growing. Method provides stimulation of factors of cellular and humoral immunity of animals without adverse reactions and complication due to selection of optimal dose of immunomodulator and its prolonged effect.

EFFECT: improved method for treatment and prophylaxis.

3 cl, 4 tbl, 3 ex

Up!